Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma
Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the feasibility and toxicity of the combination of
paclitaxel, carboplatin, and topotecan in patients with previously untreated, stage III or IV
epithelial ovarian carcinoma or primary peritoneal carcinoma. We will also make a preliminary
evaluation of the efficacy of this three drug regimen in the initial treatment of these
patients.